Darren M Brenner1, Emily Stern2, Brooks D Cash3. 1. Northwestern University-Feinberg School of Medicine, 676 N. Saint Clair Ave Suite 1400, Chicago, IL, 60611, USA. darren-brenner@northwestern.edu. 2. Northwestern University-Feinberg School of Medicine, 676 N. Saint Clair Ave Suite 1400, Chicago, IL, 60611, USA. 3. University of South Alabama, Mobile, AL, USA.
Abstract
PURPOSE OF REVIEW: Opioids are a mainstay in the treatment of chronic non-cancer pain syndromes, but their analgesic benefits come at a cost as opioid-related constipation occurs in 40-80% of individuals taking chronic opioids. Furthermore, as 10-20% of the population suffers from constipation at baseline, it should be expected that while a proportion of individuals will develop constipation as a direct consequence of opioids (OIC), others will experience it as an exacerbation of their baseline constipation (OEC). Herein, we review the evidence-based data for treatments directed at opioid-related constipation focusing on individuals with non-cancer pain syndromes and provide a template for the development of differentiated treatment algorithms for OIC and OEC. RECENT FINDINGS: Historical and current treatment protocols recommend traditional laxatives, but these are ineffective in up to 50%, due in part to the heterogeneous pathogenesis of constipation. Therapeutic decisions must be tailored to account for this overlapping pathogenesis. OIC and OEC are distinct entities. As such, additional research and guidelines should address these as different patient populations.
PURPOSE OF REVIEW: Opioids are a mainstay in the treatment of chronic non-cancer pain syndromes, but their analgesic benefits come at a cost as opioid-related constipation occurs in 40-80% of individuals taking chronic opioids. Furthermore, as 10-20% of the population suffers from constipation at baseline, it should be expected that while a proportion of individuals will develop constipation as a direct consequence of opioids (OIC), others will experience it as an exacerbation of their baseline constipation (OEC). Herein, we review the evidence-based data for treatments directed at opioid-related constipation focusing on individuals with non-cancer pain syndromes and provide a template for the development of differentiated treatment algorithms for OIC and OEC. RECENT FINDINGS: Historical and current treatment protocols recommend traditional laxatives, but these are ineffective in up to 50%, due in part to the heterogeneous pathogenesis of constipation. Therapeutic decisions must be tailored to account for this overlapping pathogenesis. OIC and OEC are distinct entities. As such, additional research and guidelines should address these as different patient populations.
Authors: Shrividya S Iyer; Bruce P Randazzo; Evan L Tzanis; Seth L Schulman; Haiying Zhang; Wenjin Wang; Amy L Manley Journal: Value Health Date: 2011-01 Impact factor: 5.725
Authors: Michael Camilleri; Adil E Bharucha; Ryuji Ueno; Duane Burton; George M Thomforde; Kari Baxter; Sanna McKinzie; Alan R Zinsmeister Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-05 Impact factor: 4.052
Authors: Laxmaiah Manchikanti; Salahadin Abdi; Sairam Atluri; Carl C Balog; Ramsin M Benyamin; Mark V Boswell; Keith R Brown; Brian M Bruel; David A Bryce; Patricia A Burks; Allen W Burton; Aaron K Calodney; David L Caraway; Kimberly A Cash; Paul J Christo; Kim S Damron; Sukdeb Datta; Timothy R Deer; Sudhir Diwan; Ike Eriator; Frank J E Falco; Bert Fellows; Stephanie Geffert; Christopher G Gharibo; Scott E Glaser; Jay S Grider; Haroon Hameed; Mariam Hameed; Hans Hansen; Michael E Harned; Salim M Hayek; Standiford Helm; Joshua A Hirsch; Jeffrey W Janata; Alan D Kaye; Adam M Kaye; David S Kloth; Dhanalakshmi Koyyalagunta; Marion Lee; Yogesh Malla; Kavita N Manchikanti; Carla D McManus; Vidyasagar Pampati; Allan T Parr; Ramarao Pasupuleti; Vikram B Patel; Nalini Sehgal; Sanford M Silverman; Vijay Singh; Howard S Smith; Lee T Snook; Daneshvari R Solanki; Deborah H Tracy; Ricardo Vallejo; Bradley W Wargo Journal: Pain Physician Date: 2012-07 Impact factor: 4.965
Authors: Fermín Mearin; Brian E Lacy; Lin Chang; William D Chey; Anthony J Lembo; Magnus Simren; Robin Spiller Journal: Gastroenterology Date: 2016-02-18 Impact factor: 22.682
Authors: M Camilleri; D A Drossman; G Becker; L R Webster; A N Davies; G M Mawe Journal: Neurogastroenterol Motil Date: 2014-08-28 Impact factor: 3.598
Authors: Adam D Farmer; Asbjørn M Drewes; Giuseppe Chiarioni; Roberto De Giorgio; Tony O'Brien; Bart Morlion; Jan Tack Journal: United European Gastroenterol J Date: 2018-12-14 Impact factor: 4.623
Authors: Darren M Brenner; Charles E Argoff; Susan M Fox; Wieslaw Bochenek; Patricia D'Astoli; Rick E Blakesley; David S Reasner; Christopher R O'Dea; Brooks D Cash Journal: Pain Date: 2020-05 Impact factor: 7.926
Authors: Isabel Neves Duarte Lisboa; Jéssica Dantas De Sá Tinôco; Maria Isabel Da Conceição Dias Fernandes; Rammila Rayara Da Silva; Juliana Barbosa Da Silva; Millena Freire Delgado; Marcos Venícios Oliveira Lopes; Ana Luisa Brandão De Carvalho Lira Journal: Asian Pac J Cancer Prev Date: 2021-09-01